BioSpace News Archive

Viridian Therapeutics, Inc. today announced that senior management will participate in the 5th Annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022.

Replay, a genome writing company reprogramming biology by writing and delivering big DNA, today announced that it has received a $1.56 million grant from the Bill & Melinda Gates Foundation to accelerate the development of uCell™, a proprietary hypoimmunogenic technology platform.

XORTX Therapeutics Inc. is pleased to announce the successful screening and enrollment of the last remaining subjects into the XRX-OXY-101 Bridging Pharmacokinetics Study.

Exscientia plc (Nasdaq: EXAI) today announced clinical trial application (CTA) approval of IGNITE-AI, enabling site activation in its first European country.

BrainsWay Ltd. today reported that David Zacut, M.D., BrainsWay’s Chairman of the Board of Directors, and Avner Hagai, an independent Director on BrainsWay’s Board, separately purchased BrainsWay ordinary shares in recent open market purchases.

Two Industry Veterans Join Already Strong Team MENLO PARK, Calif.--( BUSINESS WIRE )-- LevitasBio, Inc., a premier end-to-end sample processing and cellular analysis provider to the life sciences market, announced the hiring of Dominique Remy-Renou as its Senior Vice President of Global Commercial Operations of LevitasBio Europe BV, and the appointment of Greg Herrema to its Board of Directors. The addition of two Life Sciences veterans bring decades of biotech industry expertise

Onconova Therapeutics, Inc. today announced that it will participate in the RHK Capital Disruptive Growth Conference being held in the offices of Reed Smith in New York, NY on December 5-6, 2022.

Galectin Therapeutics Inc. announced today the Company will be presenting at the 6 th Obesity and NASH Drug Development Summit in Boston, MA.

Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, announced the closing of a $120 million Series C financing.

Oxitope is pleased to announce the appointment of Professor Gregg Stone as a clinical key opinion leader for its lead antibody programme targeting myocardial infarction induced reperfusion injury.